Evidence map›Paper›PMID 42422179›Full record

ReviewFrontiers in cardiovascular medicine2026

Deep vein thrombosis as a public health priority: wHO's agenda for Africa 2030.

Emmanuel Ifeanyi Obeagu

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Emmanuel Ifeanyi ObeaguDivision of Haematology, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep vein thrombosis (DVT) is a serious vascular condition characterized by the formation of blood clots in deep veins, predominantly in the lower limbs. Despite its significant morbidity and mortality worldwide, DVT remains an under-recognized public health issue in Africa, where limited awareness, diagnostic challenges, and resource constraints contribute to suboptimal prevention and management. The rising burden of risk factors such as obesity, HIV infection, infectious diseases, and sedentary lifestyles highlights the urgent need to prioritize DVT within the continent's healthcare agenda. The World Health Organization (WHO) has identified the control of DVT as a critical component of its 2030 health strategy for Africa, emphasizing integration into non-communicable disease and cardiovascular health programs. Strategic priorities include enhancing epidemiological surveillance, increasing healthcare provider and community awareness, strengthening diagnostic capacity, and implementing evidence-based thromboprophylaxis guidelines. However, challenges such as inadequate infrastructure, limited access to anticoagulant therapies, and sociocultural barriers hinder effective DVT control across many African settings. Addressing these challenges requires a coordinated, multisectoral approach that incorporates capacity building, resource mobilization, and policy reforms aligned with WHO's vision. By elevating DVT as a public health priority, African nations can improve early detection, prevention, and management of venous thromboembolism, ultimately reducing preventable complications and improving vascular health outcomes across the continent.

Indexed as

2030 health goalsAfricadeep vein thrombosispublic healthWHO agenda

Identifiers

PMID42422179
PMCPMC13341813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.